Emerging evidence suggests that commonly used medicines such as beta‐blockers (BBs), angiotensin‐converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), metformin, statins and PPIs may impact the therapeutic outcomes of patients with breast cancer [6, 7, 8, 9, 10, 11, 12, 13]. This evidence concerns the gene ACE and breast carcinoma.